Everest receives Singapore HSA approval for NEFEGAN to treat IgAN

2024-03-20

临床结果临床3期上市批准申请上市

Everest receives Singapore HSA approval for NEFEGAN to treat IgAN

Preview

来源: Pharmaceutical Technology

NEFEGAN demonstrated clinically meaningful results over placebo. Credit: Peakstock via Shutterstock.

Everest Medicines has received approval from the Singapore Health Sciences Authority (HSA) for NEFEGAN to treat primary immunoglobulin A nephropathy (IgAN) in adults at disease progression risk.

An oral, delayed-release budesonide formulation, NEFEGAN is also known as Nefecon in other regions and is the first medication for IgAN, having received the first full approval from the US Food and Drug Administration.

Singapore is the third region within Everest’s territories to approve the new drug application (NDA), following mainland China and Macao.

The efficacy and safety of Nefecon were evaluated in the Phase III NefIgArd clinical trial.

This randomised, double-blind, multicentre study tested a once-a-day dose of 16mg Nefecon against a placebo in adults with primary IgAN who were also receiving optimised angiotensin system inhibitors therapy.

See Also:

Johnson & Johnson’s paediatric HIV-1 treatment secures FDA approval

Preview

来源: Pharmaceutical Technology

FDA approves Boehringer’s SPEVIGO for psoriasis treatment

Preview

来源: Pharmaceutical Technology

Spanning over two years, the NefIgArd trial included nine months of treatment with either Nefecon or a placebo, succeeded by a follow-up period of 15 months without the study drug.

The time-weighted average of the estimated glomerular filtration rate (eGFR) over two years was the trial’s primary endpoint.

The findings showed that Nefecon offered a statistically significant and clinically meaningful benefit over a placebo.

Additionally, the trial demonstrated a favourable two-year total eGFR slope difference of 2.95ml per minute and 1.73m² per year with Nefecon treatment.

These benefits were consistent across the entire study population, irrespective of the baseline level of urine protein-creatinine ratio.

An in-depth analysis of the full two-year results from the NefIgArd trial, which involved 364 patients, was conducted to examine the response to Nefecon treatment based on self-reported ancestry.

Among the participants, 83 identified as Asian and 275 as White. In both subgroups, Nefecon’s 16mg a day dosage over nine months led to a clinically meaningful preservation of kidney function, with a reduction in proteinuria and stabilisation of eGFR compared to placebo.

Everest CEO Rogers Yongqing Luo said: “The NDA approval in Singapore marks an important event for IgAN patients in the region as we continue to expand patient access to Nefecon throughout Asia, an area of high IgAN disease prevalence.

“Following approval of Nefecon in mainland China and commercial launch in Macao, we are working to rapidly expand availability of this first-in-disease therapy which targets the origin of the disease and can slow disease progression to more underserved patients in 2024, including Hong Kong, Taiwan and South Korea.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构